The manufacture of radiopharmaceuticals under current Good Manufacturing Practice (cGMP) conditions represents one of the most technically demanding frontiers in modern pharmaceutical production, where the intersection of radioactive decay kinetics, aseptic processing, and stringent quality assurance creates a uniquely challenging operational environment. At Protheragen, our cGMP manufacturing facility service is engineered to bridge the gap between innovative radiopharmaceutical discovery and reliable commercial supply, offering partners a fully integrated environment where preclinical concepts mature into patient-ready therapeutic and diagnostic products.
A cGMP manufacturing facility for radiopharmaceuticals is a purpose-built infrastructure designed to handle the dual challenges of radioactive material containment and sterile pharmaceutical production. Unlike conventional drug manufacturing, these facilities must accommodate short-lived radioisotopes—ranging from minutes to days in half-life—while maintaining aseptic conditions that meet international pharmaceutical standards. The core architecture typically integrates lead-shielded hot cells for radiochemistry synthesis, modular cleanroom suites graded for sterile operations, dedicated quality control laboratories, and specialized HVAC systems that manage both particulate contamination and radioactive airborne emissions. Hot cells serve as the primary workstations where radioisotopes are received, chemically manipulated, and formulated into drug products, with shielding thickness calibrated to the energy spectrum of specific radionuclides such as fluorine-18, lutetium-177, or actinium-225.
Fig 1. Flowchart of quality risk assessment methodology to be applied to production of sterile PET radiopharmaceuticals under GMP regulations. (Poli, Michela, et al., 2024)
The facility design follows a unidirectional flow principle: raw materials and inactive precursors enter through controlled airlocks, progress through synthesis and formulation zones, and exit as finished doses via shielded dispensing and packaging lines. Environmental monitoring is continuous, encompassing differential pressure tracking across cleanroom zones, airborne particle counting, and surface contamination surveys. Because radiopharmaceutical decay is irreversible and time-dependent, production scheduling is synchronized with clinical administration timelines, making facility throughput and logistical coordination as critical as chemical yield. Modern cGMP facilities also incorporate automated synthesis modules, robotic dispensing systems, and real-time data acquisition to minimize human radiation exposure while maximizing batch-to-batch consistency.
Protheragen operates as a full-spectrum Radiopharmaceutical CRDMO and CRO, extending its capabilities from early-stage preclinical research and IIT clinical studies through to commercial-scale cGMP production. Our manufacturing infrastructure is purpose-built to address the unique demands of radiopharmaceutical synthesis, combining shielded radiochemistry suites, modular sterile cleanrooms, and integrated quality control laboratories under one operational umbrella. Whether your program requires small-batch clinical trial material for a first-in-human study or multi-kilogram commercial campaigns for a marketed therapeutic, Protheragen provides the technical depth, regulatory rigor, and operational agility to keep your product on schedule and within specification. By partnering with us, you gain access to a team that understands the critical interplay between isotope half-life, chemical yield, and sterile release timelines—ensuring that every batch is manufactured with precision and delivered with confidence.
We translate laboratory-scale radiochemistry into robust, reproducible cGMP processes. Our team optimizes reaction parameters, purification strategies, and formulation conditions to maximize radiochemical yield while minimizing impurities. Scale-up activities are conducted with a clear path toward commercial validation, ensuring that process changes between clinical phases are controlled and documented.
Our facility houses lead-shielded hot cells equipped with automated synthesis modules and remote manipulator systems, enabling safe handling of alpha, beta, and positron-emitting isotopes. Radiolabeling of peptides, antibodies, small molecules, and macrocyclic chelators is performed under controlled conditions with real-time monitoring of temperature, pressure, and radioactivity.
Final drug product formulation occurs within ISO-classified cleanroom environments, utilizing laminar-flow isolators and closed-system filling technologies. We perform aseptic filling into vials or syringes, followed by secure capping, labeling, and shielded packaging—ensuring that each dose meets sterility assurance levels required for parenteral administration.
Our on-site QC laboratories conduct comprehensive analytical testing including radiochemical purity assessment, radionuclidic identity verification, pH determination, osmolality measurement, endotoxin screening, and sterility confirmation. Each batch is reviewed by qualified personnel before release, with full traceability from raw material receipt to finished product dispatch.
Given the radioactive decay characteristics of radiopharmaceuticals, we design and execute stability programs that account for both chemical degradation and physical half-life. Real-time and accelerated stability data support shelf-life claims, storage condition definitions, and in-use period justifications for regulatory submissions.
We manage seamless technology transfer from client laboratories or third-party developers into our cGMP facility, including process documentation, analytical method validation, and regulatory filing support. Our CMC packages are structured to facilitate IND, clinical trial, and commercial application submissions across multiple jurisdictions.
The cGMP manufacturing workflow for radiopharmaceuticals is a time-critical, multi-stage process that demands precise coordination between radiochemistry, pharmaceutical processing, and quality assurance. Each step is designed to maximize product yield, ensure sterility, and maintain compliance while accounting for the relentless progression of radioactive decay. Below is the sequential flow from project initiation to batch release.
If you are advancing a radiopharmaceutical program and require a cGMP manufacturing partner with the technical depth, regulatory experience, and operational flexibility to support your clinical or commercial ambitions, we invite you to reach out to us. The Protheragen team is ready to discuss your specific manufacturing requirements, review facility compatibility, and outline a tailored engagement strategy that aligns with your development timeline. Whether your project is in early process development or preparing for commercial launch, contact us today to explore how our cGMP manufacturing facility service can become the reliable backbone of your radiopharmaceutical supply chain.
Reference